US20010008637A1 - Two-part capsule to accept pharmaceutical preparations for powder inhalers - Google Patents
Two-part capsule to accept pharmaceutical preparations for powder inhalers Download PDFInfo
- Publication number
- US20010008637A1 US20010008637A1 US09/800,647 US80064701A US2001008637A1 US 20010008637 A1 US20010008637 A1 US 20010008637A1 US 80064701 A US80064701 A US 80064701A US 2001008637 A1 US2001008637 A1 US 2001008637A1
- Authority
- US
- United States
- Prior art keywords
- capsule
- cap
- capsule according
- capsules
- elevations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
- A61J3/072—Sealing capsules, e.g. rendering them tamper-proof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Definitions
- the invention relates to new two-part capsules for holding pharmaceutical preparations for use in powder inhalers.
- Capsules with pharmaceutical preparations are often used in the therapy and diagnosis of illnesses.
- the capsules can be orally administered or are used in certain medical apparatus such as powder inhalers.
- the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which are pushed together telescopically.
- multi-part capsules are also known.
- the capsules generally consist of gelatine, especially hard gelatine.
- the capsules occasionally consist of water-soluble synthetic materials easily digested by humans, in order for example to release the active ingredients in certain compartments of the gastrointestinal tract in the case of oral administration. Examples of various capsule materials are listed hereinafter.
- EP 0143524 discloses a two-part capsule of material which is easily digestible by humans, preferably gelatine.
- EP 0460921 describes capsules of chitosan and starch, grain powder, oligosaccharides, methacrylic acid-methylacrylate, methacrylic acid-ethylacrylate, hydroxypropylmethylcelluloseacetate, -succinate or -phthaleate.
- the capsule material is distinguished by the contents not being released until they reach the large intestine.
- GB 938828 discloses capsules for radioactive substances used in therapy or diagnosis.
- the capsules comprise water-soluble gelatine, methylcellulose, polyvinylalcohol or water-soluble non-toxic thermoplasts.
- capsules which are specially adapted for use in powder inhalers without necessarily being subjected to the conditions for oral administration, are previously not known in the prior art.
- the capsules for powder inhalers comprise the same materials as are used for oral administration, usually hard gelatine. However, these materials are not specially perfected for use in powder inhalers.
- One of the objectives of the present invention is to provide capsules which can be better adapted to the special conditions in powder inhalers.
- the capsules which have hitherto been used in powder inhalers have various disadvantages as a result of their composition.
- materials used in construction of the capsules can alter their characteristics dependent on the ambient air humidity and/or do not always have sufficient inherent stability.
- such a capsule cannot for example be used in climatic zone 4 as a result of the high air humidity, since the capsule material absorbs the humidity to such a degree that the inherent stability is seriously affected and/or the humidity penetrates into the interior of the capsule. This has a negative effect on the pharmaceutical quality of the capsule's contents.
- the said materials also have diverse disadvantages in other various stages in the life of the capsule from manufacturing up to utilisation, which affect the suitability of the capsule as a carrier for pharmaceutical preparations, the manner of administration of the contents, the perishability of the contents and/or the usability of the capsule in certain countries.
- a further disadvantage of conventional capsule materials is that e.g. they tend to bind powder materials to themselves, especially when coated with a mould release agent which is often necessary for production of the capsule. In the case of capsules for inhalation purposes, this leads to difficulty in accurately metering the fine fraction which is to enter the lungs.
- a further objective of the present invention is to provide capsules for powder inhalers which do not have the aforementioned problems of conventional capsules.
- the present invention relates to a capsule for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to use in powder inhalers.
- the capsules consist of water-insoluble, hydrophobic synthetic materials, which do not themselves substantially influence the pharmaceutical quality of the contents, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the climatic zone, and are advantageous at various stages from production through to utilisation.
- the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which can be connected together so as to form a stable enclosed hollow space of defined volume which contains the pharmaceutical formulation.
- the dimensions of the capsule are chosen so that the capsule can be used with common powder inhalers which are used with capsules, such as those described for example in patent documents DE 33 45 722 (Inhaler Ingelheim M), EP 0 591 136 (Inhaler Ingelheim) or in the published German application DE 43 18 455 (“HandiHaler®”).
- the synthetic material of the capsule is not digestible by humans, so that the active ingredient is not released when the capsule is taken orally. This has the advantage that inadvertent swallowing of the capsule cannot lead to a detrimental effect on health. This applies especially to small children or older people.
- synthetic materials are used which can be processed using injection moulding or blow casting and/or synthetic materials where no mould release agent is necessary for their processing into capsule caps or capsule bodies, which can cause adhesion of the contents to the capsule wall.
- This has the advantage that the interior of the cap or the body need not be cleaned from mould separation agent, in order for example to meet the official requirements (e.g. according to DAB (Deutsches maschiner Buch)), which restricts the use of mould release agents for primary packaging means.
- the synthetic material does not exhibit any pronounced adhesion for pharmaceutical-chemical materials, especially for particles of lung-accessible size, so that when the capsule is used in one of the aforementioned inhalers, the entire contents of the capsule can be released.
- This has the advantage that exact dosage, especially of the lung-accessible fine fraction, is possible.
- the capsule consists of a synthetic material with a Shore hardness D of 65 to 73.
- a synthetic material of this hardness does not shatter when it is pierced or cut open, but at the same time it is rigid enough so that the resulting hole does not close up again.
- the advantage of such material is that no fragments can be forced out of the capsule during opening, piercing or slicing open of the capsule in the powder inhaler which can be breathed in during inhalation.
- the synthetic material capsule is so stable that it can withstand a force along its longitudinal axis or transverse axis of up to 15 N.
- the advantage of this is that the capsule is better adapted to the stress which acts upon it during manufacture, filling, packaging, transportation and the like.
- the wall of the capsule has a steam permeability of less than 1.3 ⁇ 10 ⁇ 14 kg/(m 2 s Pa), preferably of 1.5 ⁇ 10 ⁇ 16 to 2 ⁇ 10 ⁇ 16 kg/(m 2 s Pa).
- the synthetic material is polyethylene, especially polyethylene with a density of between 9000 and 10,000 kg/m 3 , preferably 9600 kg/m 3 (high-density polyethylene), polycarbonate, polyester, polypropylene or polyethyleneterephthalate.
- the cap and the body have the shape of a cylinder with a round cross-section and a convex, practically hemispherical closed underside, and both consist of high-density polyethylene with a density of between 9500 and 10000 kg/m 3 .
- the capsules according to the invention can be used in all kinds of powder inhalers where the preparation which is to be inhaled is administered by means of a capsule.
- the cap and body of the capsule are of mutually-similar cylindrical shape, comprising an inherently closed jacket with, in each case, a closed end and an open end.
- the shape and size of the cap and the capsule are such that the body can be pushed telescopically into the open end of the cap with its open end, so that the cap is attached solidly to the body.
- the cap and body are provided with locking devices, which are advantageous for temporary and/or final closure of the capsule.
- the elevations there are point-shaped elevations on the inner jacket of the cap and on the outer jacket of the body there are somewhat larger point-shaped recesses which are arranged so that the elevations engage with the recesses on closure of the capsule.
- the elevations can be located on the outer jacket of the body and the recesses on the inner jacket of the cap. Arrangements are preferred where the elevations or recesses are respectively disposed in a ring or spiral shape about the jacket. Instead of the point-shaped design of the elevations and recesses, these can also run continuously around the cap or the body in a ring-shape.
- one or more elevations running annularly around the inner jacket of the cap and the outer jacket of the body, are designed so that elevations on the cap are each positioned next to an elevation of the body when the capsule is closed.
- annular recesses and/or elevations can be continuous or interrupted.
- elevations are formed on the outside of the body near the open end and holes are formed in the cap near the open end so that the elevations of the body locate into the holes in the cap when the capsule is closed.
- the elevations can be designed so that the cap can be opened at any time without damage to the capsule, or so that once closed, the capsule can no longer be opened without being damaged.
- a bulge is designed on the outer side of the body, which runs around the body perpendicular to the connecting axis between the cap and the body.
- the bulge serves as a stopper for the capsule when this is placed over the body, in order to prevent piercing of the cap with the body.
- the area between the open end of the body and the bulge corresponds to the area of the body over which the cap can be pushed.
- the bulge is located on the body so that the cap can be pushed far enough over the body to ensure good attachment between the cap and the body. That is, the bulge may not, for example, be located directly on the open side of the body.
- the side of the bulge which faces the open end of the body stands as a vertical edge on the outer wall of the body so that the cap cannot be pushed over the bulge on closure.
- the side of the bulge which faces towards the closed end of the body can be designed in the form of an almost right-angled edge or can taper towards the closed end of the body.
- the formation of a practically right-angled edge can be advantageous where the capsule fits loosely into the capsule holder, whilst the version with the tapering bulge can be advantageous in the case of a tight fit.
- the bulge can be continuous or interrupted.
- the bulge tapers continuously to the closed end of the body and stands with its end oriented towards the open end of the body perpendicularly on the capsule body.
- the height of the edge thus formed is such that, in the closed position of the capsule, the edge does not project beyond the cap, thus providing a flat transition from the cap to the body.
- the thickness of the walls of the cap and the body can vary over the entire area.
- the wall thickness is generally greater in the rounded areas of the cap or the body, or at that point in the body where the bulge is formed, than in the areas where the walls run straight.
- the walls of the cap and the body have a thickness of 0.1 to 0.5 mm.
- knobs are formed on the outside of the capsule, and in another embodiment there are three or more ribs, which run parallel to the longitudinal axis of the capsule.
- the advantage of these devices is that the capsule can be removed from a capsule holder e.g. as used in the aforementioned powder inhalers, in such a way that it does not get damaged or break open.
- the ribs or the knobs can run around the entire outside of the capsule or may only cover a part thereof. Alternatively, they may only be provided on the cap or only in the area of the body which is visible from outside in its closed state.
- the ribs run parallel to the longitudinal axis of the capsule and ensure that the capsule is fixed vertically in the aforementioned capsule holder.
- the ribs are preferably arranged so that the cross-section of the capsule does not have rotational symmetry about its central axis.
- the ribs may be provided only in the area of the body which is visible when the capsule is closed. This embodiment prevents the capsule jamming in a capsule holder.
- the ribs are designed so that the ends of the ribs which are orientated towards the open end of the body perform the function of the bulge, namely to act as a stopper for the cap, when the cap is attached to the body.
- the jackets of the cap and the body describe a hollow cylinder with a round, oval, triangular, quadrilateral, hexagonal, octagonal or polygonal cross-section, where the respective upper side is open and the underside is closed.
- the closed underside can be flat or convex.
- the angled embodiments have the advantage that they can for example be stored in a more space-saving manner than the round embodiments.
- the elongation of the capsule (distance from the closed end of the body to the closed end of the cap in relation to the diameter when the capsule is closed) is greater than 1, in one embodiment the elongation is 1 and in yet another embodiment the elongation is smaller than 1.
- the latter has the advantage that the body has a larger opening for filling.
- the cap and the body are designed so that the closed capsule is spherical, which can be advantageous for automatic loading of a powder inhaler with the capsule from a reservoir.
- the joint between the cap and the body when the filled capsules are closed can be welded, adhesively bonded or wrapped, thus reducing the steam permeability to as little as a tenth.
- the entire cap can be covered with a protective film.
- the gap may be sealed with a filler.
- Suitable fillers for filling the gap in this way are the pharmaceutically acceptable fillers such as Eudragit.
- a filler of this kind can be inserted in the gap as a solution or suspension in a suitable, preferably highly volatile solvent.
- Suitable solvents include fluorochlorohydrocarbons such as methylene chloride or chloroform, fluorohydrocarbons, alcohols such as methanol, ethanol, propanol, isopropanol, alkanes such as propane, hexane, heptane, ketones such as acetone, esters such as ethyl acetate, ethers such as dimethylether or diethylether or other liquids known from the prior art to be suitable for solutions or suspensions, especially volatile liquids and those which do not attack the capsule material, do not interact chemically with pharmaceutical compositions or alter their bioavailability.
- fluorochlorohydrocarbons such as methylene chloride or chloroform
- fluorohydrocarbons such as methylene chloride or chloroform
- alcohols such as methanol, ethanol, propanol, isopropanol
- alkanes such as propane, hexane, heptane
- ketones such as
- the solution or suspension with the filler must be of a nature and concentration such that the solution or suspension delivers sufficient filler into the gap so that, after the solvent has evaporated, the filler left behind provides a tight seal and at the same time the solution or suspension should not be of a nature and concentration such that it is too viscous to penetrate into the gap or be drawn into it by capillary action.
- a solution of Eudragit and acetone is used to seal the gap.
- the capsule is suitable for holding any kind of powdered pharmaceutical preparation which is suitable for inhalation.
- the capsule contains cromoglycic acid, reproterol, beclomethasone, terbutaline, salbutamol, salmeterol, ketotifen, orciprenaline, fluticasone, insulin, ipratropium, dexamethasone, bambuterol, tiotropium, budesonide, fenoterol, clenbuterol, prednisolone, prednisone, prednylidene, methylprednisolone, formoterol, nedocromil, the salts or mixtures thereof or another cortisone preparation or atropine derivative suitable for inhalation purposes.
- the capsule contains ipratropium bromide or tiotropium bromide.
- FIG. 1 shows the simplest embodiment of the capsules according to the invention in lateral cross-section.
- FIGS. 2 a and 2 b each show a different embodiment of the capsule with a tapering bulge on the body in lateral cross-section.
- FIG. 3 shows an embodiment of the capsule with an angular bulge on the body in lateral cross-section.
- FIG. 4 shows an embodiment of the capsule with a tapering bulge on the body and annular recess on the body and cap in lateral cross-section.
- FIG. 5 shows an embodiment of the capsule with tapering bulge on the body and annular recess on the body and cap in frontal view.
- FIG. 6 shows an embodiment of the capsule with tapering bulge on the body and point-shaped recesses or elevations on the body and cap in frontal view.
- FIG. 7 shows an embodiment of the capsule with tapering bulge on the body and point-shaped elevations on the body and point-shaped holes in the cap in frontal view.
- FIG. 8 shows an embodiment of the capsule with ribs on the body in frontal view.
- FIG. 9 shows the capsule of FIG. 7 in horizontal cross-section.
- FIGS. 10 a , 10 b and 10 c show embodiments of the capsule, each with a different cross-section.
- FIG. 1 the simplest embodiment of the capsule according to the invention 1 is shown in cross-section.
- the capsule 1 consists of the cap 2 and the body 3 , which are fitted telescopically one into the other.
- the cap 2 and the body 3 are of the same shape and each has a convex underside 4 .
- FIG. 2 a shows a cross-section of an embodiment where a bulge 5 is formed on the body 3 of the capsule 1 , this bulge tapering towards the closed end of the body.
- the bulge 5 stands practically vertically on the body with its side orientated towards the open end of the body.
- the edge thus formed demarcates the area of the body over which the cap 2 can be pushed telescopically.
- FIG. 2 b Another embodiment is shown in FIG. 2 b .
- the cross-section shows that this embodiment differs from that shown in FIG. 2 a in that the wall thickness of the cap 2 or the body 3 is not uniformly great over the entire area, but rather varies over individual partial areas.
- the convex undersides 4 of the cap or the body each have a concave indentation at the vertex.
- FIG. 3 an embodiment is represented where the bulge 5 sits on the body almost at right angles to the upper side of the body and also the underside of the body.
- the embodiment of FIG. 4 represents a further development of the embodiment of FIG. 2 a , where an annular recess 6 or 7 is formed in cap 2 or body 3 in order to close the capsule 1 more satisfactorily.
- FIG. 5 shows a front view of the embodiment shown in FIG. 4 as a cross-section.
- FIG. 6 shows a further variant of the invention with point-shaped recesses 8 and 9 in front view.
- FIG. 7 a variant of the capsule 1 is shown where elevations 10 are provided on the body 3 near the open end, and holes 11 are provided in the cap 2 near the open end so that the elevations 10 engage with the holes 11 when the capsule is closed.
- FIG. 8 shows an embodiment of the capsule 1 from outside, where ribs 12 are provided on the body 3 .
- FIG. 9 shows the body 3 of the embodiment in FIG. 7 in cross-section.
- the cross-section shows that the three ribs 12 are not arranged with rotational symmetry about the central axis of the body.
- FIGS. 10 a , 10 b and 10 c show a capsule 1 of quadrilateral, triangular and octagonal cross-section, respectively.
Abstract
The present invention relates to capsules for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to their use in powder inhalers. The capsules consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality of the contents themselves, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the geographic location of their use, and are advantageous at various stages from manufacture up to utilisation.
Description
- The invention relates to new two-part capsules for holding pharmaceutical preparations for use in powder inhalers.
- Capsules with pharmaceutical preparations are often used in the therapy and diagnosis of illnesses. The capsules can be orally administered or are used in certain medical apparatus such as powder inhalers. Generally, the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which are pushed together telescopically. However, multi-part capsules are also known. The capsules generally consist of gelatine, especially hard gelatine. In the case of some special applications, the capsules occasionally consist of water-soluble synthetic materials easily digested by humans, in order for example to release the active ingredients in certain compartments of the gastrointestinal tract in the case of oral administration. Examples of various capsule materials are listed hereinafter.
- EP 0143524 discloses a two-part capsule of material which is easily digestible by humans, preferably gelatine.
- EP 0460921 describes capsules of chitosan and starch, grain powder, oligosaccharides, methacrylic acid-methylacrylate, methacrylic acid-ethylacrylate, hydroxypropylmethylcelluloseacetate, -succinate or -phthaleate. The capsule material is distinguished by the contents not being released until they reach the large intestine.
- GB 938828 discloses capsules for radioactive substances used in therapy or diagnosis. The capsules comprise water-soluble gelatine, methylcellulose, polyvinylalcohol or water-soluble non-toxic thermoplasts.
- The materials which are used are often not very resistant to air humidity, which is why the pharmaceutical quality of the contents cannot be guaranteed for all climatic zones. Especially in climatic zone 4 (30° C./70% relative air humidity), conventional capsules cannot be used.
- Two-part capsules, which are specially adapted for use in powder inhalers without necessarily being subjected to the conditions for oral administration, are previously not known in the prior art. The capsules for powder inhalers comprise the same materials as are used for oral administration, usually hard gelatine. However, these materials are not specially perfected for use in powder inhalers.
- One of the objectives of the present invention is to provide capsules which can be better adapted to the special conditions in powder inhalers.
- The capsules which have hitherto been used in powder inhalers have various disadvantages as a result of their composition. Hence materials used in construction of the capsules can alter their characteristics dependent on the ambient air humidity and/or do not always have sufficient inherent stability. As a result, such a capsule cannot for example be used in climatic zone4 as a result of the high air humidity, since the capsule material absorbs the humidity to such a degree that the inherent stability is seriously affected and/or the humidity penetrates into the interior of the capsule. This has a negative effect on the pharmaceutical quality of the capsule's contents. The said materials also have diverse disadvantages in other various stages in the life of the capsule from manufacturing up to utilisation, which affect the suitability of the capsule as a carrier for pharmaceutical preparations, the manner of administration of the contents, the perishability of the contents and/or the usability of the capsule in certain countries. A further disadvantage of conventional capsule materials is that e.g. they tend to bind powder materials to themselves, especially when coated with a mould release agent which is often necessary for production of the capsule. In the case of capsules for inhalation purposes, this leads to difficulty in accurately metering the fine fraction which is to enter the lungs.
- A further objective of the present invention is to provide capsules for powder inhalers which do not have the aforementioned problems of conventional capsules.
- The present invention relates to a capsule for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to use in powder inhalers. The capsules consist of water-insoluble, hydrophobic synthetic materials, which do not themselves substantially influence the pharmaceutical quality of the contents, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the climatic zone, and are advantageous at various stages from production through to utilisation.
- The capsules, according to the invention, consist of two parts, a capsule body (body) and a capsule cap (cap), which can be connected together so as to form a stable enclosed hollow space of defined volume which contains the pharmaceutical formulation. The dimensions of the capsule are chosen so that the capsule can be used with common powder inhalers which are used with capsules, such as those described for example in patent documents DE 33 45 722 (Inhaler Ingelheim M), EP 0 591 136 (Inhaler Ingelheim) or in the published German application DE 43 18 455 (“HandiHaler®”).
- In one embodiment, the synthetic material of the capsule is not digestible by humans, so that the active ingredient is not released when the capsule is taken orally. This has the advantage that inadvertent swallowing of the capsule cannot lead to a detrimental effect on health. This applies especially to small children or older people.
- Preferably, synthetic materials are used which can be processed using injection moulding or blow casting and/or synthetic materials where no mould release agent is necessary for their processing into capsule caps or capsule bodies, which can cause adhesion of the contents to the capsule wall. This has the advantage that the interior of the cap or the body need not be cleaned from mould separation agent, in order for example to meet the official requirements (e.g. according to DAB (Deutsches Apotheker Buch)), which restricts the use of mould release agents for primary packaging means.
- In a preferred embodiment of the invention, the synthetic material does not exhibit any pronounced adhesion for pharmaceutical-chemical materials, especially for particles of lung-accessible size, so that when the capsule is used in one of the aforementioned inhalers, the entire contents of the capsule can be released. This has the advantage that exact dosage, especially of the lung-accessible fine fraction, is possible.
- In a further embodiment, the capsule consists of a synthetic material with a Shore hardness D of 65 to 73. A synthetic material of this hardness does not shatter when it is pierced or cut open, but at the same time it is rigid enough so that the resulting hole does not close up again. The advantage of such material is that no fragments can be forced out of the capsule during opening, piercing or slicing open of the capsule in the powder inhaler which can be breathed in during inhalation.
- In one embodiment, the synthetic material capsule is so stable that it can withstand a force along its longitudinal axis or transverse axis of up to 15 N. The advantage of this is that the capsule is better adapted to the stress which acts upon it during manufacture, filling, packaging, transportation and the like.
- In a further embodiment, the wall of the capsule has a steam permeability of less than 1.3×10−14 kg/(m2 s Pa), preferably of 1.5×10−16 to 2×10−16 kg/(m2 s Pa). The advantage of this feature is that the contents of the capsule are also protected from water in geographical zones with high air humidity.
- In preferred embodiments, the synthetic material is polyethylene, especially polyethylene with a density of between 9000 and 10,000 kg/m3, preferably 9600 kg/m3 (high-density polyethylene), polycarbonate, polyester, polypropylene or polyethyleneterephthalate.
- In a preferred embodiment, the cap and the body have the shape of a cylinder with a round cross-section and a convex, practically hemispherical closed underside, and both consist of high-density polyethylene with a density of between 9500 and 10000 kg/m3.
- The capsules according to the invention can be used in all kinds of powder inhalers where the preparation which is to be inhaled is administered by means of a capsule.
- In a preferred embodiment, the cap and body of the capsule are of mutually-similar cylindrical shape, comprising an inherently closed jacket with, in each case, a closed end and an open end. Here, the shape and size of the cap and the capsule are such that the body can be pushed telescopically into the open end of the cap with its open end, so that the cap is attached solidly to the body.
- In a special embodiment, the cap and body are provided with locking devices, which are advantageous for temporary and/or final closure of the capsule.
- In such an embodiment, there are point-shaped elevations on the inner jacket of the cap and on the outer jacket of the body there are somewhat larger point-shaped recesses which are arranged so that the elevations engage with the recesses on closure of the capsule. Alternatively, the elevations can be located on the outer jacket of the body and the recesses on the inner jacket of the cap. Arrangements are preferred where the elevations or recesses are respectively disposed in a ring or spiral shape about the jacket. Instead of the point-shaped design of the elevations and recesses, these can also run continuously around the cap or the body in a ring-shape.
- In one embodiment, one or more elevations, running annularly around the inner jacket of the cap and the outer jacket of the body, are designed so that elevations on the cap are each positioned next to an elevation of the body when the capsule is closed.
- In embodiments with the aforementioned annular recesses and/or elevations, these can be continuous or interrupted.
- In a further embodiment, elevations are formed on the outside of the body near the open end and holes are formed in the cap near the open end so that the elevations of the body locate into the holes in the cap when the capsule is closed. The elevations can be designed so that the cap can be opened at any time without damage to the capsule, or so that once closed, the capsule can no longer be opened without being damaged.
- In a further embodiment, a bulge is designed on the outer side of the body, which runs around the body perpendicular to the connecting axis between the cap and the body. The bulge serves as a stopper for the capsule when this is placed over the body, in order to prevent piercing of the cap with the body. The area between the open end of the body and the bulge corresponds to the area of the body over which the cap can be pushed. The bulge is located on the body so that the cap can be pushed far enough over the body to ensure good attachment between the cap and the body. That is, the bulge may not, for example, be located directly on the open side of the body. The side of the bulge which faces the open end of the body stands as a vertical edge on the outer wall of the body so that the cap cannot be pushed over the bulge on closure. The side of the bulge which faces towards the closed end of the body can be designed in the form of an almost right-angled edge or can taper towards the closed end of the body. The formation of a practically right-angled edge can be advantageous where the capsule fits loosely into the capsule holder, whilst the version with the tapering bulge can be advantageous in the case of a tight fit. The bulge can be continuous or interrupted.
- In a preferred embodiment, the bulge tapers continuously to the closed end of the body and stands with its end oriented towards the open end of the body perpendicularly on the capsule body. The height of the edge thus formed is such that, in the closed position of the capsule, the edge does not project beyond the cap, thus providing a flat transition from the cap to the body.
- The thickness of the walls of the cap and the body can vary over the entire area. Thus, the wall thickness is generally greater in the rounded areas of the cap or the body, or at that point in the body where the bulge is formed, than in the areas where the walls run straight. In one embodiment, the walls of the cap and the body have a thickness of 0.1 to 0.5 mm.
- In one possible embodiment, knobs are formed on the outside of the capsule, and in another embodiment there are three or more ribs, which run parallel to the longitudinal axis of the capsule. The advantage of these devices is that the capsule can be removed from a capsule holder e.g. as used in the aforementioned powder inhalers, in such a way that it does not get damaged or break open. The ribs or the knobs can run around the entire outside of the capsule or may only cover a part thereof. Alternatively, they may only be provided on the cap or only in the area of the body which is visible from outside in its closed state. The ribs run parallel to the longitudinal axis of the capsule and ensure that the capsule is fixed vertically in the aforementioned capsule holder. In the case of the capsule having a circular cross-section, the ribs are preferably arranged so that the cross-section of the capsule does not have rotational symmetry about its central axis. In such an embodiment, the ribs may be provided only in the area of the body which is visible when the capsule is closed. This embodiment prevents the capsule jamming in a capsule holder. In an embodiment without a bulge but with ribs on the part of the body which is visible when the capsule is closed, the ribs are designed so that the ends of the ribs which are orientated towards the open end of the body perform the function of the bulge, namely to act as a stopper for the cap, when the cap is attached to the body.
- In a further embodiment, the jackets of the cap and the body describe a hollow cylinder with a round, oval, triangular, quadrilateral, hexagonal, octagonal or polygonal cross-section, where the respective upper side is open and the underside is closed. The closed underside can be flat or convex. The angled embodiments have the advantage that they can for example be stored in a more space-saving manner than the round embodiments.
- In one embodiment, the elongation of the capsule (distance from the closed end of the body to the closed end of the cap in relation to the diameter when the capsule is closed) is greater than 1, in one embodiment the elongation is 1 and in yet another embodiment the elongation is smaller than 1. The latter has the advantage that the body has a larger opening for filling.
- In one of the embodiments with an elongation of 1, the cap and the body are designed so that the closed capsule is spherical, which can be advantageous for automatic loading of a powder inhaler with the capsule from a reservoir.
- In order to attain better sealing between the cap and the body when the filled capsules are closed, the joint between the cap and the body can be welded, adhesively bonded or wrapped, thus reducing the steam permeability to as little as a tenth. Alternatively, the entire cap can be covered with a protective film.
- In another preferred embodiment, the gap may be sealed with a filler. Suitable fillers for filling the gap in this way are the pharmaceutically acceptable fillers such as Eudragit. A filler of this kind can be inserted in the gap as a solution or suspension in a suitable, preferably highly volatile solvent. Suitable solvents include fluorochlorohydrocarbons such as methylene chloride or chloroform, fluorohydrocarbons, alcohols such as methanol, ethanol, propanol, isopropanol, alkanes such as propane, hexane, heptane, ketones such as acetone, esters such as ethyl acetate, ethers such as dimethylether or diethylether or other liquids known from the prior art to be suitable for solutions or suspensions, especially volatile liquids and those which do not attack the capsule material, do not interact chemically with pharmaceutical compositions or alter their bioavailability. The solution or suspension with the filler must be of a nature and concentration such that the solution or suspension delivers sufficient filler into the gap so that, after the solvent has evaporated, the filler left behind provides a tight seal and at the same time the solution or suspension should not be of a nature and concentration such that it is too viscous to penetrate into the gap or be drawn into it by capillary action.
- Preferably, a solution of Eudragit and acetone is used to seal the gap.
- It can be seen from the description that the capsule, according to the invention, is suitable for holding any kind of powdered pharmaceutical preparation which is suitable for inhalation. In a special application, the capsule contains cromoglycic acid, reproterol, beclomethasone, terbutaline, salbutamol, salmeterol, ketotifen, orciprenaline, fluticasone, insulin, ipratropium, dexamethasone, bambuterol, tiotropium, budesonide, fenoterol, clenbuterol, prednisolone, prednisone, prednylidene, methylprednisolone, formoterol, nedocromil, the salts or mixtures thereof or another cortisone preparation or atropine derivative suitable for inhalation purposes.
- In a preferred embodiment, the capsule contains ipratropium bromide or tiotropium bromide.
- The diagrams show various embodiments of the capsule according to the invention by way of example, but only serve to illustrate the invention without restricting its scope.
- FIG. 1 shows the simplest embodiment of the capsules according to the invention in lateral cross-section.
- FIGS. 2a and 2 b each show a different embodiment of the capsule with a tapering bulge on the body in lateral cross-section.
- FIG. 3 shows an embodiment of the capsule with an angular bulge on the body in lateral cross-section.
- FIG. 4 shows an embodiment of the capsule with a tapering bulge on the body and annular recess on the body and cap in lateral cross-section.
- FIG. 5 shows an embodiment of the capsule with tapering bulge on the body and annular recess on the body and cap in frontal view.
- FIG. 6 shows an embodiment of the capsule with tapering bulge on the body and point-shaped recesses or elevations on the body and cap in frontal view.
- FIG. 7 shows an embodiment of the capsule with tapering bulge on the body and point-shaped elevations on the body and point-shaped holes in the cap in frontal view.
- FIG. 8 shows an embodiment of the capsule with ribs on the body in frontal view.
- FIG. 9 shows the capsule of FIG. 7 in horizontal cross-section.
- FIGS. 10a, 10 b and 10 c show embodiments of the capsule, each with a different cross-section.
- An embodiment illustrating a spherical capsule is not shown.
- In FIG. 1, the simplest embodiment of the capsule according to the
invention 1 is shown in cross-section. Thecapsule 1 consists of thecap 2 and thebody 3, which are fitted telescopically one into the other. Thecap 2 and thebody 3 are of the same shape and each has a convex underside 4. - FIG. 2a shows a cross-section of an embodiment where a
bulge 5 is formed on thebody 3 of thecapsule 1, this bulge tapering towards the closed end of the body. Thebulge 5 stands practically vertically on the body with its side orientated towards the open end of the body. The edge thus formed demarcates the area of the body over which thecap 2 can be pushed telescopically. - Another embodiment is shown in FIG. 2b. The cross-section shows that this embodiment differs from that shown in FIG. 2a in that the wall thickness of the
cap 2 or thebody 3 is not uniformly great over the entire area, but rather varies over individual partial areas. In addition, the convex undersides 4 of the cap or the body each have a concave indentation at the vertex. - In FIG. 3 an embodiment is represented where the
bulge 5 sits on the body almost at right angles to the upper side of the body and also the underside of the body. The embodiment of FIG. 4 represents a further development of the embodiment of FIG. 2a, where an annular recess 6 or 7 is formed incap 2 orbody 3 in order to close thecapsule 1 more satisfactorily. - FIG. 5 shows a front view of the embodiment shown in FIG. 4 as a cross-section.
- FIG. 6 shows a further variant of the invention with point-shaped recesses8 and 9 in front view.
- In FIG. 7, a variant of the
capsule 1 is shown whereelevations 10 are provided on thebody 3 near the open end, and holes 11 are provided in thecap 2 near the open end so that theelevations 10 engage with the holes 11 when the capsule is closed. - FIG. 8 shows an embodiment of the
capsule 1 from outside, whereribs 12 are provided on thebody 3. - FIG. 9 shows the
body 3 of the embodiment in FIG. 7 in cross-section. The cross-section shows that the threeribs 12 are not arranged with rotational symmetry about the central axis of the body. FIGS. 10a, 10 b and 10 c show acapsule 1 of quadrilateral, triangular and octagonal cross-section, respectively.
Claims (15)
1. A capsule to hold a pharmaceutical preparation for powder inhalation which comprises a capsule body and a capsule cap, which are to be attached to one another so as to form a stable, enclosed hollow space of defined volume, the capsule body and the capsule cap, being made of a water-insoluble, hydrophobic synthetic material.
2. The capsule according to , characterized in that the walls of the cap and the body are 0.1 mm to 0.5 mm thick.
claim 1
3. The capsule according to , characterized in that the capsule can withstand a force acting upon its longitudinal axis and its transverse axis of up to 15 N.
claim 1
4. The capsule according to , characterized in that the Shore hardness D of the synthetic material is in the range from 65 to 73.
claim 1
5. The capsule according to , characterized in that the wall of the capsule has a steam permeability of less than 1.3×10−14 kg/(m2s Pa).
claim 1
6. The capsule according to , characterized in that the wall of the capsule has a steam permeability of 1.5×10−16 to 2×10−16 kg/(m2s Pa).
claim 5
7. The capsule according to , characterized in that the synthetic material is polyethylene, polycarbonate, polyester, polypropylene or polyethyleneterephthalate.
claim 1
8. The capsule according to , characterized in that the synthetic material is polyethylene with a density of 9,000-10,000 kg/m3.
claim 7
9. The capsule according to , characterized in that one or more elevations or recesses are located on the inner jacket of the cap and one or more recesses or elevations are located on the outer jacket of the body, these elevations or recesses being arranged so that the elevations engage with the recesses when the capsule is closed, by attaching the capsule body and the capsule cap.
claim 1
10. The capsule according to , characterized in that a bulge runs in an annular shape around the outside of the body perpendicular to the connecting axis of the cap and the body, the side of the bulge which is orientated towards the open end of the body standing practically at right angles to the outer wall of the body.
claim 1
11. The Capsule according to , characterized in that the capsule body and capsule cap are both made of high density polyethylene and are both in the shape of a cylinder of round cross section with a convex closed end, so that the elongation of the capsule (distance from the closed end of the body to the closed end of the cap in relation to the diameter when the capsule is closed) is greater than 1.
claim 1
12. The capsule according to , characterized in that the joint between the body and cap, or the gap, is sealed by welding, adhesive bonding, wrapping or covering the cap with a protective film.
claim 12
13. The capsule according to claims 12, characterized in that the joint between the body and cap, or the gap, is sealed by filling with a pharmaceutically acceptable filler.
14. The capsule according to , characterized in that the filler is Eudragit.
claim 13
15. The capsule according to which further comprises in the enclosed hollow space a pharmaceutical preparation comprising cromoglycic acid, reproterol, beclomethasone, terbutaline, albeterol, salmeterol, ketotifen, orciprenaline, fluticasone, ipratropium, dexamethasone, bambuterql, tiotropium, budesonide, fenoterol, clenbuterol, prednisolone, prednisone, prednylidene, methylprednisolone, formoterol, nedocromil, insulin,ipratropium bromide, tiotropium bromide, a salt thereof or a mixture thereof or another cortisone preparation or atropine derivative, which pharmaceutical preparation is suitable for inhalation.
claim 1
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/800,647 US20010008637A1 (en) | 1998-08-05 | 2001-03-07 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US10/740,225 US20040131668A1 (en) | 1998-08-05 | 2003-12-18 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US11/970,982 US8298575B2 (en) | 1998-08-05 | 2008-01-08 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19835346A DE19835346A1 (en) | 1998-08-05 | 1998-08-05 | Two-part capsule for pharmaceutical preparations for powder inhalers |
DE19835346.4 | 1998-08-05 | ||
US11321498P | 1998-12-22 | 1998-12-22 | |
US36591299A | 1999-08-03 | 1999-08-03 | |
US09/800,647 US20010008637A1 (en) | 1998-08-05 | 2001-03-07 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US36591299A Continuation | 1998-08-05 | 1999-08-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/740,225 Continuation US20040131668A1 (en) | 1998-08-05 | 2003-12-18 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010008637A1 true US20010008637A1 (en) | 2001-07-19 |
Family
ID=7876530
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/800,647 Abandoned US20010008637A1 (en) | 1998-08-05 | 2001-03-07 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US10/740,225 Abandoned US20040131668A1 (en) | 1998-08-05 | 2003-12-18 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US11/970,982 Expired - Fee Related US8298575B2 (en) | 1998-08-05 | 2008-01-08 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/740,225 Abandoned US20040131668A1 (en) | 1998-08-05 | 2003-12-18 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US11/970,982 Expired - Fee Related US8298575B2 (en) | 1998-08-05 | 2008-01-08 | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
Country Status (35)
Country | Link |
---|---|
US (3) | US20010008637A1 (en) |
EP (1) | EP1100474B1 (en) |
JP (1) | JP2002522378A (en) |
KR (1) | KR100622291B1 (en) |
CN (1) | CN1151779C (en) |
AR (1) | AR023640A1 (en) |
AT (1) | ATE220542T1 (en) |
AU (1) | AU763266B2 (en) |
BG (1) | BG64115B1 (en) |
BR (1) | BR9912748A (en) |
CA (1) | CA2338323C (en) |
CZ (1) | CZ301558B6 (en) |
DE (2) | DE19835346A1 (en) |
DK (1) | DK1100474T5 (en) |
EA (1) | EA002186B1 (en) |
EE (1) | EE04451B1 (en) |
ES (1) | ES2180325T3 (en) |
HK (1) | HK1037975A1 (en) |
HU (1) | HU224955B1 (en) |
ID (1) | ID28290A (en) |
IL (2) | IL141124A0 (en) |
MY (1) | MY117930A (en) |
NO (1) | NO329078B1 (en) |
NZ (1) | NZ509977A (en) |
PL (1) | PL191231B1 (en) |
PT (1) | PT1100474E (en) |
SI (1) | SI1100474T1 (en) |
SK (1) | SK283568B6 (en) |
TR (1) | TR200100355T2 (en) |
TW (1) | TWI221420B (en) |
UA (1) | UA71920C2 (en) |
UY (1) | UY25637A1 (en) |
WO (1) | WO2000007572A2 (en) |
YU (1) | YU49388B (en) |
ZA (1) | ZA200100796B (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049311A1 (en) * | 2001-01-30 | 2003-03-13 | Mcallister Stephen Mark | Pharmaceutical formulation |
US20030125350A1 (en) * | 1999-02-08 | 2003-07-03 | Hassan Ian F. | Combination of formoterol and a tiotropium salt |
US20040115256A1 (en) * | 2001-01-30 | 2004-06-17 | Macallister Stephen Mark | Pharmaceutical formulation |
US20040136919A1 (en) * | 2002-11-28 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
US20040159322A1 (en) * | 2003-01-14 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
US20050084457A1 (en) * | 2001-06-01 | 2005-04-21 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
US20050175687A1 (en) * | 2001-01-30 | 2005-08-11 | Mcallister Stephen M. | Pharmaceutical formulations |
US20050249807A1 (en) * | 2004-03-12 | 2005-11-10 | Adrian Brown | Pharmaceutical formulations |
US20060157054A1 (en) * | 2005-01-11 | 2006-07-20 | Boehringer Lngelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
US7163693B1 (en) | 1999-07-30 | 2007-01-16 | Smithkline Beecham Plc | Multi-component pharmaceutical dosage form |
US20070107722A1 (en) * | 2005-11-15 | 2007-05-17 | Hubert Hoelz | Needle for piercing a powder capsule for inhalation |
US20080160076A1 (en) * | 1998-08-05 | 2008-07-03 | Dieter Hochrainer | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US20090110721A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Paneled capsule shells for release of pharmaceutical compositions |
US20090108492A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Method and apparatus for manufacturing filled linkers |
US20090110723A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms |
US20100022790A1 (en) * | 2008-07-24 | 2010-01-28 | Christian Dussarrat | Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors |
US20100074947A1 (en) * | 2008-06-13 | 2010-03-25 | Adrian Brown | Pharmaceutical Formulations |
US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
US8673350B2 (en) | 2003-07-21 | 2014-03-18 | Capsugel Belgium Nv | Pharmaceutical formulations |
US20150136131A1 (en) * | 2011-05-27 | 2015-05-21 | Boehringer Ingelheim GmbH, Corporate Patents | System composed of inhaler and capsule |
US20180318171A1 (en) * | 2017-05-03 | 2018-11-08 | Garry Tsaur | capsule sealing composition and its sealing method thereof |
US20200197633A1 (en) * | 2014-11-09 | 2020-06-25 | Sipnose Ltd | Bfs-ffs devices and methods for delivering a substance to a body cavity |
US10888675B2 (en) * | 2016-02-24 | 2021-01-12 | Boehringer Ingelheim International Gmbh | Inhaler |
CN113933237A (en) * | 2021-10-20 | 2022-01-14 | 山西信谊通制药有限公司 | Amoxicillin capsule detection device and use method thereof |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10062712A1 (en) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and corticosteroids |
WO2002036106A2 (en) * | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament compositions based on anticholinergics and corticosteroids |
DE10063957A1 (en) * | 2000-12-20 | 2002-06-27 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and dopamine agonists |
DE10056104A1 (en) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
DE10126924A1 (en) * | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability |
DE10137054A1 (en) * | 2001-07-28 | 2003-02-13 | Boehringer Ingelheim Pharma | Sealing plastic capsules containing inhalable drug, by welding telescopically fitting capsule parts by applying jet of hot gas or a laser beam to overlapping regions during relative movement |
US6949154B2 (en) | 2001-07-28 | 2005-09-27 | Boehringer Ingelheim Pharma Kg | Method and apparatus for sealing medicinal capsules |
GB0122031D0 (en) * | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
US6941980B2 (en) | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
US20040043064A1 (en) * | 2002-08-29 | 2004-03-04 | Iorio Theodore L. | Dosage forms having reduced moisture transmission |
US7699052B2 (en) | 2002-09-05 | 2010-04-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Apparatus for the dispensing of liquids, container cartridge suitable for this, and system comprising the apparatus for the dispensing of liquids, and the container cartridge |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
DE10258360A1 (en) * | 2002-12-12 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Chamber for accommodation of disposable capsules for powder inhalers has an inner surface with protruding elements serving as distance pieces between the capsules |
AU2003302274A1 (en) * | 2002-12-31 | 2004-07-29 | Novartis Ag | Aerosolizable pharmaceutical formulation for fungal infection therapy |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
DE10300984A1 (en) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Capsule for taking up an active ingredient that can be administered by inhalation |
ES2564165T3 (en) | 2003-04-09 | 2016-03-18 | Novartis Ag | Aerosolization device with alignment guide for capsule drilling |
US8869794B1 (en) | 2003-04-09 | 2014-10-28 | Novartis Pharma Ag | Aerosolization apparatus with capsule puncturing member |
ES2383367T5 (en) | 2003-04-09 | 2021-03-31 | Novartis Ag | Aerosol spray device with air intake protection |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
DE102004012973B4 (en) * | 2004-03-17 | 2006-03-23 | Josef Eckert | Capsule for holding at least one pharmaceutical preparation, in particular for powder inhalers, and capsule chain consisting of several such capsules |
AU2005258040A1 (en) | 2004-06-21 | 2006-01-05 | Novartis Ag | Compositions comprising amphotericin b |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
US8210171B2 (en) | 2004-09-13 | 2012-07-03 | Oriel Therapeutics, Inc. | Tubular dry powder drug containment systems, associated inhalers and methods |
GB0503738D0 (en) * | 2005-02-23 | 2005-03-30 | Optinose As | Powder delivery devices |
DE102005022862A1 (en) * | 2005-05-18 | 2006-12-14 | Airsec S.A.S | Capsules for inhalers |
US8377471B2 (en) * | 2005-08-09 | 2013-02-19 | Capsugel Belgium Nv | Container |
NL1033047C2 (en) * | 2006-12-13 | 2008-06-16 | Pharmachemie Bv | Capsule filled with a medicine, in particular an inhalable medicine. |
DE102007033861A1 (en) | 2007-07-20 | 2009-07-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhaler for inhalation of powdered medicaments, has lower part, which is closed with lockable plate, and operating organ is mounted at plate and capsule holder and is enhanced |
DE102007036411A1 (en) | 2007-07-20 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
ATE555768T1 (en) | 2007-10-19 | 2012-05-15 | Capsugel Belgium Nv | CONTAINER WITH MULTIPLE COMPARTMENTS |
DE102007052871A1 (en) | 2007-11-02 | 2009-05-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Capsule for receiving pharmaceutical drug formulations |
DE102007058112A1 (en) | 2007-12-03 | 2009-06-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler with active ingredient tablet |
CA2707906A1 (en) * | 2007-12-05 | 2009-06-18 | Novartis Ag | Receptacle for an aerosolizable pharmaceutical formulation |
WO2009140587A1 (en) | 2008-05-15 | 2009-11-19 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
AT507631B1 (en) | 2008-11-26 | 2012-05-15 | Haas Rouven Mag | DEVICE FOR INTAKING POWDER OR GRANULATE MATERIAL AND CAPSULE THEREFOR |
PL2413902T3 (en) | 2009-03-18 | 2020-01-31 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
US8746244B2 (en) | 2009-10-02 | 2014-06-10 | Boehringer Ingelheim International Gmbh | Powder inhaler |
TR200909790A2 (en) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Combination of dry powder containing a combination of tiotropium, formoterol and a chromoglycic acid derivative. |
US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
DE102010002604A1 (en) * | 2010-03-05 | 2011-09-08 | Robert Bosch Gmbh | Capsule, useful for receiving a medium, preferably medical preparations, comprises a capsule lower part with an outwardly curved, inner hollow ridge to incorporate a medium, and a capsule upper part attached on capsule lower part |
EP2614848B1 (en) | 2012-01-13 | 2020-07-01 | Boehringer Ingelheim International GmbH | Inhaler and capsule for an inhaler |
WO2013174752A2 (en) | 2012-05-21 | 2013-11-28 | Boehringer Ingelheim International Gmbh | System composed of inhaler and capsule |
DE202011102694U1 (en) | 2011-06-29 | 2011-12-19 | Zisser Gmbh | Inhaler for home users |
EP2852423B1 (en) * | 2012-05-21 | 2018-07-11 | Boehringer Ingelheim International GmbH | Inhaler and capsule for an inhaler |
WO2016014153A1 (en) * | 2014-07-23 | 2016-01-28 | Microdose Therapeutx, Inc. | Dry powder nebulizer |
DE102015108931B3 (en) * | 2015-06-05 | 2016-06-09 | Gerresheimer Regensburg Gmbh | Grid element for an inhaler |
DE102015109996B3 (en) | 2015-06-22 | 2016-07-28 | Gerresheimer Regensburg Gmbh | Device for opening capsules |
KR101748796B1 (en) | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | Inhalation capsule with enhanced delivery rate of active ingredients |
SG11201805788WA (en) | 2016-02-01 | 2018-08-30 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
JP7185529B2 (en) | 2016-02-24 | 2022-12-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | inhaler |
KR20200003199A (en) | 2017-05-10 | 2020-01-08 | 인카다 테라퓨틱스, 인크. | Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration |
EP3600303A4 (en) | 2017-08-15 | 2020-12-16 | Thomas Julius Borody | Compositions, devices and methods for treating autism |
EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | A novel method to slow ventricular rate |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US596591A (en) | 1898-01-04 | Track device for operating signals | ||
GB691696A (en) | 1950-10-05 | 1953-05-20 | Becton Dickinson Co | Improvements relating to hypodermic injection apparatus |
US2718980A (en) | 1951-10-02 | 1955-09-27 | Robinson William H | Container seal |
NL269886A (en) | 1960-10-04 | |||
US3285408A (en) | 1964-10-16 | 1966-11-15 | Lilly Co Eli | Capsule with integral locking band |
US3623997A (en) * | 1966-06-06 | 1971-11-30 | Ncr Co | Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material |
US3949751A (en) | 1970-03-03 | 1976-04-13 | Fisons Limited | Method and device for dispensing medicament to the body |
US3664495A (en) | 1970-12-21 | 1972-05-23 | Parke Davis & Co | Locking capsule |
IT941426B (en) | 1971-07-17 | 1973-03-01 | Isf Spa | SWIRL-CHAMBER INHALER FOR POWDER-SHAPING MEDICINAL SUBSTANCES |
US3823843A (en) | 1972-10-26 | 1974-07-16 | Lilly Co Eli | Locking capsule |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
IT1016489B (en) | 1974-03-18 | 1977-05-30 | Isf Spa | INHALER |
US4040536A (en) | 1975-05-05 | 1977-08-09 | R. P. Scherer Corporation | Locking hard gelatin capsule |
US4880547A (en) * | 1975-06-30 | 1989-11-14 | Kenji Etani | Methods for water treatment |
US4692314A (en) * | 1975-06-30 | 1987-09-08 | Kenji Etani | Water treatment systems |
JPS5352619A (en) | 1976-10-25 | 1978-05-13 | Shin Etsu Chem Co Ltd | Enteric capsule |
GB1598081A (en) * | 1977-02-10 | 1981-09-16 | Allen & Hanburys Ltd | Inhaler device for dispensing medicaments |
DE2722822C2 (en) | 1977-05-20 | 1984-11-08 | Capsugel AG, Basel | Method for producing a push-fit capsule suitable for receiving a viscous substance, in particular a liquid medicament |
US4192304A (en) * | 1978-03-14 | 1980-03-11 | Johnson & Johnson | Intravenous catheter assembly with fluid flow restriction capability |
US4192309A (en) * | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
BR8007911A (en) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | PERFECTED INHALER |
CY1308A (en) * | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
ES506585A0 (en) * | 1980-10-30 | 1982-09-01 | Riker Laboratories Inc | A DEVICE TO FACILITATE THE ORAL INHALATION OF MEDICINES IN THE FORM OF POWDER |
GB2095497B (en) | 1981-03-24 | 1984-08-15 | Racal Communications Equip | Improvements in and relating to direction finding |
DE3371865D1 (en) * | 1982-10-29 | 1987-07-09 | Warner Lambert Co | Tamper-resistant capsules |
US4656066A (en) | 1982-12-20 | 1987-04-07 | Warner-Lambert Company | Apparatus and method for sealing capsules |
US4533542A (en) * | 1983-08-22 | 1985-08-06 | Eli Lilly And Company | Pharmaceutical compositions for storage in plastic containers and process therefor |
US4535567A (en) | 1983-08-26 | 1985-08-20 | Seaborn Development, Inc. | Computer magnetic media burnisher |
GB8325529D0 (en) * | 1983-09-23 | 1983-10-26 | Lilly Industries Ltd | Medicinal forms |
US4738724A (en) * | 1983-11-04 | 1988-04-19 | Warner-Lambert Company | Method for forming pharmaceutical capsules from starch compositions |
DE3345722A1 (en) | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | INHALATOR |
US4667498A (en) * | 1984-06-29 | 1987-05-26 | Sauter Manufacturing Corp. | Method and apparatus of making gelatine capsule forming pins having a rounded locking groove |
US4883182A (en) * | 1985-05-31 | 1989-11-28 | Hughes Raymond J | Tamper evident capsule and insert device |
US4648532A (en) * | 1986-05-09 | 1987-03-10 | Green Russell D | Mixing and discharge capsule |
US4793493A (en) * | 1986-09-18 | 1988-12-27 | Makiej Jr Walter J | Multidose capsules |
KR890003520Y1 (en) | 1986-12-20 | 1989-05-27 | 주식회사 서흥캅셀 | Medicinal capsule |
GB8721455D0 (en) * | 1987-09-11 | 1987-10-21 | Lilly Industries Ltd | Capsules |
US4863017A (en) * | 1988-11-09 | 1989-09-05 | Vlock D G | Amalgam capsule |
US5342624A (en) * | 1989-02-16 | 1994-08-30 | British Technology Group Ltd. | Dispensing device |
IT1228460B (en) | 1989-02-23 | 1991-06-19 | Phidea S R L | DISPOSABLE INHALER WITH PRE-PERFORATED CAPSULE |
DE3927170A1 (en) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | INHALATOR |
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
JPH064531B2 (en) | 1990-06-04 | 1994-01-19 | アイセロ化学株式会社 | Colon disintegrating hard capsule |
CA2115648C (en) * | 1991-10-10 | 2002-04-09 | Eun Soo Lee | Osmotic drug delivery devices with hydrophobic wall materials |
US5417337A (en) * | 1991-11-12 | 1995-05-23 | Robbins, Iii; Edward S. | Reusable and re-collapsible container and associated cap |
JPH0774149B2 (en) | 1991-12-27 | 1995-08-09 | 藤本製薬株式会社 | Hard gelatin capsule |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5388698A (en) * | 1992-02-03 | 1995-02-14 | Wakao; Hiroshi | Pocket carrier for dispensing products in precise quantitites |
GB9223172D0 (en) * | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Capsule construction |
GB9223144D0 (en) | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Controlled release device |
EP0597136A1 (en) | 1992-11-08 | 1994-05-18 | Prenco Ag | Device for purifying and extracting welding fumes |
DE4318455A1 (en) | 1993-06-03 | 1994-12-08 | Boehringer Ingelheim Kg | Capsule holder |
US5396986A (en) * | 1993-06-16 | 1995-03-14 | Special Metals Corporation | Mixing capsule having three tubular members |
US5498255A (en) | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
JPH07118143A (en) | 1993-10-18 | 1995-05-09 | Bayer Yakuhin Kk | Lag time control type capsule |
FR2715299B1 (en) * | 1994-01-21 | 1996-06-14 | Georges Serge Grimberg | Medicine with a pediatric presentation facilitating its absorption by a child. |
PT101450B (en) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | NEW INHALATION DEVICE |
US5641510A (en) | 1994-07-01 | 1997-06-24 | Genentech, Inc. | Method for treating capsules used for drug storage |
JP3455789B2 (en) | 1995-02-28 | 2003-10-14 | 株式会社大塚製薬工場 | Film for multi-chamber container and multi-chamber container |
JP3028641U (en) | 1995-09-23 | 1996-09-13 | スー ヘング カプセル カンパニー リミテッド | Drug or food capsule |
KR0124764Y1 (en) | 1995-09-23 | 1998-09-15 | 양주환 | Medical capsule |
JPH09104060A (en) | 1995-10-12 | 1997-04-22 | Sumitomo Bakelite Co Ltd | Drug packing polypropylene sheet and production thereof |
JPH09193963A (en) | 1996-01-19 | 1997-07-29 | Material Eng Tech Lab Inc | Wrapping method of resin container filled with carbonate or bicarbonate |
JP3328132B2 (en) | 1996-03-21 | 2002-09-24 | 株式会社ユニシアジェックス | Inhaler type dispenser |
PT101988B (en) | 1997-04-04 | 2004-02-27 | Hovione Farmaciencia Sa | SYSTEM OF ORIENTATION AND POSITIONING OF AN OBJECT |
GB9805102D0 (en) | 1998-03-10 | 1998-05-06 | Ciba Geigy Ag | Device |
DE19835346A1 (en) | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Two-part capsule for pharmaceutical preparations for powder inhalers |
DE19961311A1 (en) * | 1999-12-18 | 2001-07-26 | Bayerische Motoren Werke Ag | Battery sensor device, has attachment device, sensor combined into integrated unit; attachment device is connected to single pole and has conventional terminal |
US6949154B2 (en) * | 2001-07-28 | 2005-09-27 | Boehringer Ingelheim Pharma Kg | Method and apparatus for sealing medicinal capsules |
JP3750994B2 (en) * | 2001-11-16 | 2006-03-01 | 東京応化工業株式会社 | Positive photoresist composition and method for forming thin-film resist pattern for inclined implantation process |
JP4739672B2 (en) * | 2001-12-21 | 2011-08-03 | ネクター セラピューティクス | Capsule package with moisture barrier |
US20030183548A1 (en) * | 2002-04-02 | 2003-10-02 | Oertel Fritz J. | Packing capsule |
MXPA04010990A (en) * | 2002-05-07 | 2005-02-14 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same. |
US6941980B2 (en) * | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
US6941954B1 (en) | 2003-02-20 | 2005-09-13 | Michele Belcher | Fingernail protection device |
DE10352277A1 (en) | 2003-11-08 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
-
1998
- 1998-08-05 DE DE19835346A patent/DE19835346A1/en not_active Withdrawn
-
1999
- 1999-03-08 UA UA2001031523A patent/UA71920C2/en unknown
- 1999-08-03 IL IL14112499A patent/IL141124A0/en active IP Right Grant
- 1999-08-03 TR TR2001/00355T patent/TR200100355T2/en unknown
- 1999-08-03 EE EEP200100073A patent/EE04451B1/en not_active IP Right Cessation
- 1999-08-03 YU YU5401A patent/YU49388B/en unknown
- 1999-08-03 UY UY25637A patent/UY25637A1/en not_active IP Right Cessation
- 1999-08-03 DE DE59902055T patent/DE59902055D1/en not_active Expired - Lifetime
- 1999-08-03 EP EP99944325A patent/EP1100474B1/en not_active Expired - Lifetime
- 1999-08-03 BR BR9912748-2A patent/BR9912748A/en not_active Application Discontinuation
- 1999-08-03 WO PCT/EP1999/005614 patent/WO2000007572A2/en active IP Right Grant
- 1999-08-03 KR KR1020017001462A patent/KR100622291B1/en not_active IP Right Cessation
- 1999-08-03 ID IDW20010274A patent/ID28290A/en unknown
- 1999-08-03 CN CNB998092657A patent/CN1151779C/en not_active Expired - Lifetime
- 1999-08-03 AU AU57304/99A patent/AU763266B2/en not_active Expired
- 1999-08-03 EA EA200100176A patent/EA002186B1/en not_active IP Right Cessation
- 1999-08-03 ES ES99944325T patent/ES2180325T3/en not_active Expired - Lifetime
- 1999-08-03 JP JP2000563258A patent/JP2002522378A/en active Pending
- 1999-08-03 AT AT99944325T patent/ATE220542T1/en active
- 1999-08-03 PT PT99944325T patent/PT1100474E/en unknown
- 1999-08-03 CZ CZ20010444A patent/CZ301558B6/en not_active IP Right Cessation
- 1999-08-03 SI SI9930089T patent/SI1100474T1/en unknown
- 1999-08-03 SK SK169-2001A patent/SK283568B6/en not_active IP Right Cessation
- 1999-08-03 HU HU0103490A patent/HU224955B1/en unknown
- 1999-08-03 TW TW088113240A patent/TWI221420B/en not_active IP Right Cessation
- 1999-08-03 DK DK99944325T patent/DK1100474T5/en active
- 1999-08-03 PL PL346168A patent/PL191231B1/en unknown
- 1999-08-03 CA CA002338323A patent/CA2338323C/en not_active Expired - Lifetime
- 1999-08-03 NZ NZ509977A patent/NZ509977A/en not_active IP Right Cessation
- 1999-08-03 AR ARP990103868A patent/AR023640A1/en active Pending
- 1999-08-04 MY MYPI99003330A patent/MY117930A/en unknown
-
2001
- 2001-01-26 IL IL141124A patent/IL141124A/en not_active IP Right Cessation
- 2001-01-26 BG BG105189A patent/BG64115B1/en active Active
- 2001-01-29 ZA ZA200100796A patent/ZA200100796B/en unknown
- 2001-01-31 NO NO20010535A patent/NO329078B1/en not_active IP Right Cessation
- 2001-03-07 US US09/800,647 patent/US20010008637A1/en not_active Abandoned
- 2001-12-19 HK HK01108874A patent/HK1037975A1/en not_active IP Right Cessation
-
2003
- 2003-12-18 US US10/740,225 patent/US20040131668A1/en not_active Abandoned
-
2008
- 2008-01-08 US US11/970,982 patent/US8298575B2/en not_active Expired - Fee Related
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298575B2 (en) | 1998-08-05 | 2012-10-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US20080160076A1 (en) * | 1998-08-05 | 2008-07-03 | Dieter Hochrainer | Two-part capsule to accept pharmaceutical preparations for powder inhalers |
US20060083692A1 (en) * | 1999-02-08 | 2006-04-20 | Hassan Ian F | Combination of formoterol and a tiotropium salt |
US20030125350A1 (en) * | 1999-02-08 | 2003-07-03 | Hassan Ian F. | Combination of formoterol and a tiotropium salt |
US20100119597A1 (en) * | 1999-07-30 | 2010-05-13 | Clarke Allan J | Multi-component pharmaceutical dosage form |
US7163693B1 (en) | 1999-07-30 | 2007-01-16 | Smithkline Beecham Plc | Multi-component pharmaceutical dosage form |
US8440224B2 (en) | 1999-07-30 | 2013-05-14 | Capsugel Belgium Nv | Multi-component pharmaceutical dosage form |
US7691407B2 (en) | 1999-07-30 | 2010-04-06 | Smithkline Beecham Plc | Multi-component pharmaceutical dosage form |
US20070087049A1 (en) * | 1999-07-30 | 2007-04-19 | Smithkline Beecham Plc | Multi-Component Pharmaceutical Dosage Form |
US20050175687A1 (en) * | 2001-01-30 | 2005-08-11 | Mcallister Stephen M. | Pharmaceutical formulations |
US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
US8361498B2 (en) | 2001-01-30 | 2013-01-29 | Capsugel Belgium Nv | Pharmaceutical formulation |
US8367101B2 (en) | 2001-01-30 | 2013-02-05 | Capsugel Belgium Nv | Pharmaceutical formulation |
US20110123608A1 (en) * | 2001-01-30 | 2011-05-26 | Smithkline Beecham Limited | Pharmaceutical formulation |
US20040115256A1 (en) * | 2001-01-30 | 2004-06-17 | Macallister Stephen Mark | Pharmaceutical formulation |
US20030068369A1 (en) * | 2001-01-30 | 2003-04-10 | Mcallister Stephen Mark | Pharmaceutical formulation |
US20030049311A1 (en) * | 2001-01-30 | 2003-03-13 | Mcallister Stephen Mark | Pharmaceutical formulation |
US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
US20050084457A1 (en) * | 2001-06-01 | 2005-04-21 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
US20090137621A1 (en) * | 2001-06-01 | 2009-05-28 | Boehringer Ingelheim Pharma Kg | Capsules Containing Inhalable Tiotropium |
US20040136919A1 (en) * | 2002-11-28 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
US7878193B2 (en) * | 2003-01-14 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
US20090181191A1 (en) * | 2003-01-14 | 2009-07-16 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
US20040159322A1 (en) * | 2003-01-14 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
US8001965B2 (en) | 2003-01-14 | 2011-08-23 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
US8673350B2 (en) | 2003-07-21 | 2014-03-18 | Capsugel Belgium Nv | Pharmaceutical formulations |
US20070178156A1 (en) * | 2004-03-12 | 2007-08-02 | Adrian Brown | Pharmaceutical formulations |
US8147871B2 (en) | 2004-03-12 | 2012-04-03 | Capsugel Belgium Bvba | Pharmaceutical formulations |
US20050249807A1 (en) * | 2004-03-12 | 2005-11-10 | Adrian Brown | Pharmaceutical formulations |
US8662076B2 (en) * | 2005-01-11 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
US20060157054A1 (en) * | 2005-01-11 | 2006-07-20 | Boehringer Lngelheim Pharma Gmbh & Co. Kg | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers |
US9604017B2 (en) * | 2005-11-15 | 2017-03-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Needle for piercing a powder capsule for inhalation |
US20070107722A1 (en) * | 2005-11-15 | 2007-05-17 | Hubert Hoelz | Needle for piercing a powder capsule for inhalation |
US8454992B2 (en) | 2007-10-15 | 2013-06-04 | Capsugel Belgium Nv | Paneled capsule shells for release of pharmaceutical compositions |
US20090108492A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Method and apparatus for manufacturing filled linkers |
US20090110721A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Paneled capsule shells for release of pharmaceutical compositions |
US20090110723A1 (en) * | 2007-10-15 | 2009-04-30 | Mcallister Stephen Mark | Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms |
US8293159B2 (en) | 2007-10-15 | 2012-10-23 | Capsugel Belgium | Method and apparatus for manufacturing filled linkers |
US20100074947A1 (en) * | 2008-06-13 | 2010-03-25 | Adrian Brown | Pharmaceutical Formulations |
US8236979B2 (en) | 2008-07-24 | 2012-08-07 | American Air Liquide, Inc. | Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors |
US20100022790A1 (en) * | 2008-07-24 | 2010-01-28 | Christian Dussarrat | Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors |
US10500355B2 (en) * | 2011-05-27 | 2019-12-10 | Boehringer Ingelheim International Gmbh | System composed of inhaler and capsule |
US20150136131A1 (en) * | 2011-05-27 | 2015-05-21 | Boehringer Ingelheim GmbH, Corporate Patents | System composed of inhaler and capsule |
US20200197633A1 (en) * | 2014-11-09 | 2020-06-25 | Sipnose Ltd | Bfs-ffs devices and methods for delivering a substance to a body cavity |
US10888675B2 (en) * | 2016-02-24 | 2021-01-12 | Boehringer Ingelheim International Gmbh | Inhaler |
US20180318171A1 (en) * | 2017-05-03 | 2018-11-08 | Garry Tsaur | capsule sealing composition and its sealing method thereof |
US10729619B2 (en) * | 2017-05-03 | 2020-08-04 | Garry Tsaur | Capsule sealing composition and its sealing method thereof |
CN113933237A (en) * | 2021-10-20 | 2022-01-14 | 山西信谊通制药有限公司 | Amoxicillin capsule detection device and use method thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2338323C (en) | Two-piece capsule for receiving pharmaceutical preparations for powder inhalers | |
EP1883400B1 (en) | Inhalator capsules | |
US8662076B2 (en) | Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers | |
JP4866242B2 (en) | Inhaler | |
MXPA01001312A (en) | Two-piece capsule for receiving pharmaceutical preparations for powder inhalers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |